



# Synthesis of new furo[2,3-d] pyrimidine derivatives as potential inhibitors of DHFR

Marcelle de Souza Ferreira and José Daniel Figueroa Villar\*

Department of Chemistry, Military Institute of Engineering, Praça General Tibúrcio 80, 22290-270, Rio de Janeiro, RJ, Brazil. (figueroa@ime.ub.br)


Keywords: benzylidene barbiturate, furo[2,3-d]pyrimidine, DHFR

## INTRODUCTION

Heterocyclic compounds are promising agents in the development of synthetic molecules with bioactivity. Fused heterocyclic structures containing pyrimidine or furan rings exhibited diverse biological activities such as antimicrobial, anti-inflammatory, antiviral and anticancer.<sup>1</sup> The furo[2,3-d]pyrimidines, which are an important class of heterocyclic compounds, have been considered for many years as a model for the discovery of drugs for inhibition of the enzyme dihydrofolate reductase (DHFR).<sup>2</sup> In view of this biological activity, the objective of this work consists on the synthesis of new furo[2,3-d]pyrimidines as potential agents to act as antifolates inhibiting DHFR, which is present in various fungi, bacteria and protozoa. These compounds may be new agents for neglected diseases.

## RESULTS AND DISCUSSION


The methodology for the synthesis of furo[2,3-d]pyrimidine derivatives (**5**) consists of 2 steps as shown in **Figure 1**. The first step consists on the synthesis of benzylidene barbiturate (**3**) through of the Knoevenagel condensation reaction between of aromatic aldehyde (**1**) and the barbituric acid (**2**) at room temperature for 40 min. In the second step, the furo[2,3-d]pyrimidine was formed by reaction of the benzylidene barbiturate with cyclohexyl isonitrile (**4**) in dry dioxane under reflux for 3h.



**Figure 1.** Synthesis of new furo[2,3-d] pyrimidine derivatives (**5**)

15<sup>th</sup> Brazilian Meeting on Organic Synthesis – 15<sup>th</sup> BMOS – November 10-13, 2013 - Campos do Jordão, Brazil

The method to prepare furo[2,3-d]pyrimidines was invented by our research group in 1992,<sup>3</sup> using N,N-dimethyl-benzylidene barbiturates. That reaction was never executed with non N-alkylated barbiturates, process that we invented. The reaction of isonitriles with non N-methylated benzylidene barbiturates need low polarization of the exocyclic C=C bond to avoid Michael addition and induce 1+4 cycloaddition<sup>4</sup> (**Figure 2**).



**Figure 2.** Mechanism of reaction of the isonitrile with the benzylidene barbiturate

All compounds were characterized by IR and NMR. The <sup>1</sup>H RMN spectrum of furo[2,3-d]pyrimidine (**5**) showed a doublet signal in 8.67 ppm, relative to the N-H connected to the cyclohexane ring and overlapping multiplets on the region of 1.25-1.84 ppm, relative to methylene groups of the cyclohexyl ring. The <sup>13</sup>C RMN spectrum showed the 24.30, 25.57 and 32.45 ppm signals relative to methylene groups of the cyclohexyl ring and 107.61, 134.92, 162.17 ppm signals of carbons of the furan ring.

## CONCLUSION

This new developed method for preparation of furo[2,3-d]pyrimidines is only effective on less polarized benzylidene barbiturates, a process that requires the presence of electronic attractive groups on the aromatic ring. These furo[2,3-d] pyrimidine derivatives (**5a** and **5b**) and others that are synthesized will be evaluated biologically for inhibition the enzyme DHFR.

## ACKNOWLEDGEMENTS

We thank CAPES, INBEB and CNPQ for financial support.

## REFERENCES

- Maghsoodlou, M.T.; et col. *Mol. Divers.* **2011**, 15, 227.
- Gangjee, A.; et col. *Bioorg. Med. Chem.* **2009**, 17, 7324.
- Figueroa-Villar, J.D.; et col. *Heterocycles* **1992**, 34, 891.
- Figueroa-Villar, J.D.; et col. *J. Mol. Struct.* **2013**, 134, 310.